Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Sep 23, 2011

Premium

Quanterix this week appointed Martin Madaus as CEO. Madaus had been serving as the company's acting CEO and chairman of the board of directors, a position that he will retain.

Previously Madaus was president, chairman, and CEO of Millipore, which was acquired by Merck KGaA last year. Before that we was president, CEO, and head of North American operations for Roche Diagnostics.


Leroy Hood received this week the Julio Palmaz Award for Innovation in Healthcare and the Biosciences from BioMed SA, a non-profit corporation focused on promoting San Antonio's biotechnology sector.

Hood is the president and co-founder of the Institute of Systems Biology, as well as a founder of more than a dozen biotechnology firms including Applied Biosystems, Amgen, and Integrated Diagnostics.


Brian Paegel received this week a National Institutes of Health Director's New Innovator Award, which will provide him with $1.5 million in funding over five years.

Paegel is an assistant professor in the Department of Chemistry at the Scripps Research Institute. He plans to use the award to develop new tools for protein sequencing.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.